Mergers & Acquisitions ·
Supernus Pharmaceuticals, Inc. announced a proposed merger of equals with Indivior Pharmaceuticals Inc., creating a…
SUPNSupernus, Inc.
Supernus Pharmaceuticals, Inc. announced a proposed merger of equals with Indivior Pharmaceuticals Inc., creating a leading U.S. biopharmaceutical company focused on central nervous system diseases. The all-stock transaction is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals. Jack A. Khattar will serve as CEO of the combined entity. The merged company will combine Supernus's franchises (Qelbree, Zurzuvae, Onapgo, Gocovri) with Indivior's (Sublocade, Suboxone), generating approximately $2.16 billion in trailing twelve-month net revenue as of June 30, 2026. The filing references a Special Dividend funded by additional indebtedness to be incurred by the combined company. Supernus Pharmaceuticals operates in the biopharmaceutical industry, developing and commercializing treatments for central nervous system disorders.